CAP’s analysis found that for executives in the data set who did receive a bump to their salary, the median increase was 5.7% ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

With a first-in-class approval in China, Eli Lilly’s GLP-1 development engine has delivered yet again on the obesity front—although local biopharma outfit Innovent Biologics will be the one to ...

As the weight loss treatment space reaches a new saturation point, Novo Nordisk, Eli Lilly and their closest—but still distant—competitors continue to vie for a greater share of the ever- expanding ...

Revenues for the segment hit $12.3 billion for the quarter ended March 31, led by growth in Google Cloud Platform core and AI-related products which was “ much higher than Cloud’s overall revenue ...

CalMatters spoke with a number of migrants about their arrests and detentions after the first weekend of LA raids. Their accounts raise potential legal questions about the government’s operation.

Kinase Inhibitors in Autoimmune Diseases Market Research 2025-2035, Featuring Pfizer, Eli Lilly and Co, Reistone Biopharma, Incyte, BMS, Galapagos, Aclaris Therapeutics, Kadmon, Sanofi, Ono - ...

The Braves have an opportunity to win another series against the Mets on Thursday night and conclude a 10-day stretch with six wins in seven tries against their NL East foes. After suffering their ...

Lilly's new plant in North Carolina, which is the company's second in the state, uses a mix of automation and robotics to crank out injectable drugs.

Eli Lilly and Novo Nordisk intensify their weight-loss drug rivalry in India as rising demand and looming generics reshape a fast-growing market.

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing than normal” given the regulatory turmoil it revealed.

Study Overview: Eli Lilly and Company is conducting a Phase 3 study titled ‘ACCLAIM-Lp (a)’ to evaluate the efficacy of Lepodisiran in reducing major adverse cardiovascular events in adults ...